Safety and Efficacy Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)

NCT03443973 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

975

Enrollment

INDUSTRY

Sponsor class

Stopped Decision to terminate development of Gantenerumab for treatment of prodromal/mild/early stage Alzheimer's disease following results of a pre-planned analysis of the safety and efficacy of Gant in Graduate I\&II (WN29922/WN39658).

Conditions

Alzheimer Disease

Interventions

DRUG: Gantenerumab
DRUG: Placebo

Sponsor

Hoffmann-La Roche